1. Home
  2. SNY vs BSX Comparison

SNY vs BSX Comparison

Compare SNY & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNY
  • BSX
  • Stock Information
  • Founded
  • SNY 1994
  • BSX 1979
  • Country
  • SNY France
  • BSX United States
  • Employees
  • SNY N/A
  • BSX N/A
  • Industry
  • SNY Biotechnology: Pharmaceutical Preparations
  • BSX Medical/Dental Instruments
  • Sector
  • SNY Health Care
  • BSX Health Care
  • Exchange
  • SNY Nasdaq
  • BSX Nasdaq
  • Market Cap
  • SNY 120.2B
  • BSX 129.7B
  • IPO Year
  • SNY N/A
  • BSX 1992
  • Fundamental
  • Price
  • SNY $47.71
  • BSX $89.09
  • Analyst Decision
  • SNY Buy
  • BSX Strong Buy
  • Analyst Count
  • SNY 2
  • BSX 23
  • Target Price
  • SNY $57.50
  • BSX $96.41
  • AVG Volume (30 Days)
  • SNY 2.7M
  • BSX 5.1M
  • Earning Date
  • SNY 01-30-2025
  • BSX 01-29-2025
  • Dividend Yield
  • SNY 4.27%
  • BSX N/A
  • EPS Growth
  • SNY N/A
  • BSX 47.19
  • EPS
  • SNY 4.00
  • BSX 1.21
  • Revenue
  • SNY $54,031,898,261.00
  • BSX $15,911,000,000.00
  • Revenue This Year
  • SNY $3.18
  • BSX $17.67
  • Revenue Next Year
  • SNY $6.67
  • BSX $12.68
  • P/E Ratio
  • SNY $23.72
  • BSX $73.58
  • Revenue Growth
  • SNY 6.01
  • BSX 15.66
  • 52 Week Low
  • SNY $45.22
  • BSX $55.60
  • 52 Week High
  • SNY $58.97
  • BSX $91.93
  • Technical
  • Relative Strength Index (RSI)
  • SNY 45.07
  • BSX 46.40
  • Support Level
  • SNY $47.01
  • BSX $89.49
  • Resistance Level
  • SNY $49.73
  • BSX $91.59
  • Average True Range (ATR)
  • SNY 0.73
  • BSX 1.40
  • MACD
  • SNY 0.16
  • BSX -0.35
  • Stochastic Oscillator
  • SNY 48.60
  • BSX 23.79

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

About BSX Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Share on Social Networks: